| 000 | 01857 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515192241.0 | ||
| 264 | 0 | _c20100729 | |
| 008 | 201007s 0 0 eng d | ||
| 022 | _a1365-2990 | ||
| 024 | 7 |
_a10.1111/j.1365-2990.2009.01047.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiu, J-R | |
| 245 | 0 | 0 |
_aThe c-Jun N-terminal kinase (JNK) inhibitor XG-102 enhances the neuroprotection of hyperbaric oxygen after cerebral ischaemia in adult rats. _h[electronic resource] |
| 260 |
_bNeuropathology and applied neurobiology _cApr 2010 |
||
| 300 |
_a211-24 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAging |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBrain _xdrug effects |
| 650 | 0 | 4 |
_aBrain Edema _xdrug therapy |
| 650 | 0 | 4 |
_aBrain Ischemia _xdrug therapy |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aHyperbaric Oxygenation _xmethods |
| 650 | 0 | 4 |
_aInfarction, Middle Cerebral Artery _xdrug therapy |
| 650 | 0 | 4 |
_aJNK Mitogen-Activated Protein Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aPeptides _xadministration & dosage |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-jun _xmetabolism |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aZhao, Y | |
| 700 | 1 | _aPatzer, A | |
| 700 | 1 | _aStaak, N | |
| 700 | 1 | _aBoehm, R | |
| 700 | 1 | _aDeuschl, G | |
| 700 | 1 | _aCulman, J | |
| 700 | 1 | _aBonny, C | |
| 700 | 1 | _aHerdegen, T | |
| 700 | 1 | _aEschenfelder, C | |
| 773 | 0 |
_tNeuropathology and applied neurobiology _gvol. 36 _gno. 3 _gp. 211-24 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2990.2009.01047.x _zAvailable from publisher's website |
| 999 |
_c19240020 _d19240020 |
||